Shares of the biopharmaceutical company, DICE Therapeutics (NASDAQ: DICE) surged in pre-market trading at the time of publishing on Tuesday after it was acquired by Eli Lilly (LLY) for a purchase price of $48 per share in cash for an aggregate value of around $2.4 billion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The acquisition is expected to close in the third quarter of this year and the purchase price indicates a premium of around 40% to the 30-day volume-weighted average trading price of DICE’s common stock ended on June 16.
Kevin Judice, Ph.D., CEO of DICE Therapeutics, stated, “We’re eager to see our pipeline, including our oral IL-17 inhibitors, DC-806 and DC-853, benefit from Lilly’s resources and global reach and I’m excited by the prospect of watching these two talented teams in a united quest for scientific innovation.
In the past year, DICE stock has surged by more than 100% in the past year.